JP2025504984A - Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト - Google Patents

Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト Download PDF

Info

Publication number
JP2025504984A
JP2025504984A JP2024545781A JP2024545781A JP2025504984A JP 2025504984 A JP2025504984 A JP 2025504984A JP 2024545781 A JP2024545781 A JP 2024545781A JP 2024545781 A JP2024545781 A JP 2024545781A JP 2025504984 A JP2025504984 A JP 2025504984A
Authority
JP
Japan
Prior art keywords
day
ibudilast
pharma
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024545781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504984A5 (OSRAM
Inventor
和子 松田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of JP2025504984A publication Critical patent/JP2025504984A/ja
Publication of JP2025504984A5 publication Critical patent/JP2025504984A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024545781A 2022-02-01 2023-01-31 Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト Pending JP2025504984A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263305483P 2022-02-01 2022-02-01
US63/305,483 2022-02-01
PCT/US2023/011931 WO2023150093A1 (en) 2022-02-01 2023-01-31 Ibudilast for use in the treatment of post-covid conditions

Publications (2)

Publication Number Publication Date
JP2025504984A true JP2025504984A (ja) 2025-02-19
JP2025504984A5 JP2025504984A5 (OSRAM) 2026-02-03

Family

ID=85382992

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024545781A Pending JP2025504984A (ja) 2022-02-01 2023-01-31 Ｃｏｖｉｄ後症状の治療における使用のためのイブジラスト

Country Status (6)

Country Link
US (1) US12171752B2 (OSRAM)
EP (1) EP4472631A1 (OSRAM)
JP (1) JP2025504984A (OSRAM)
CN (1) CN118973574A (OSRAM)
CA (1) CA3251194A1 (OSRAM)
WO (1) WO2023150093A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4828003B2 (ja) 1998-08-10 2011-11-30 杏林製薬株式会社 多発性硬化症治療薬
MX2007006777A (es) * 2004-12-06 2007-08-06 Avigen Inc Ibudilast para tratar dolor neuropatico y sindromes asociados.
US20090197823A1 (en) * 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
WO2007142924A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Ibudilast for inhibiting macrophage migration inhibitory factor (mif) activity
PT2187882E (pt) 2007-07-11 2013-04-17 Medicinova Inc Tratamento de uma doença neurodegenerativa progressiva com ibudilast
EP4132521A1 (en) * 2020-04-06 2023-02-15 MediciNova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
GB202005890D0 (en) * 2020-04-22 2020-06-03 Aivivo Ltd New uses
WO2022181219A1 (ja) * 2021-02-24 2022-09-01 国立大学法人九州大学 新興ウイルス感染症治療薬

Also Published As

Publication number Publication date
US12171752B2 (en) 2024-12-24
US20230285367A1 (en) 2023-09-14
CN118973574A (zh) 2024-11-15
EP4472631A1 (en) 2024-12-11
WO2023150093A1 (en) 2023-08-10
CA3251194A1 (en) 2023-08-10

Similar Documents

Publication Publication Date Title
CN101848712B (zh) 用异丁地特治疗渐进性神经变性疾病
US10160796B2 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
US12171752B2 (en) Methods of treating post-COVID condition(s)
JP6177765B2 (ja) 肺動脈性高血圧症の治療のためのｆｋ５０６の利用
JP2021512921A (ja) 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
JP2010506904A (ja) 精神障害の治療における抗精神病薬およびテトラサイクリンの併用療法
US20210177812A1 (en) Methods of suppressing myeloid-derived suppressor cells in patients
JP7652763B2 (ja) イブジラスト経口製剤およびその使用方法
US20230090534A1 (en) Methods of treating glioblastoma multiforme using combination therapy
US12005049B2 (en) Methods of preventing cancer metastasis
US20040219137A1 (en) Method for reducing exacerbations associated with COPD
US20220241252A1 (en) Methods of treating chemical gas exposure
JP7430719B2 (ja) イブジラストを用いて眼疾患／障害または損傷を治療する方法
US10946071B2 (en) Combination of ibudilast and interferon-beta and methods of using same
US20230116096A1 (en) Methods of minimizing cancer metastasis
US20250288561A1 (en) Nezulcitinib for delivery by nebulized oral inhalation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260126